Journals / Türkiye Acil Tıp Dergisi / 2008 / Cilt: 8 - Sayı: 3

Neuroleptic malignant syndrome: A case report

Nöroleptik malign sendrom: Bir olgu sunumu

Pages
133–135
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

By presenting this case, we aimed to discuss the approaches to NMS and treatment modalities of NMS by the light of the literature.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Neuroleptic malignant syndrome (NMS) is neurological disorder mostly caused by an adverse reaction to neuroleptic or antipsychotic drugs.
📊
Key Findings & Data:A 27-year-old male admitted to emergency department with altered mental status, speech disturbance, hyperthermia and diaphoresis.
💡
Conclusion & Impact:By presenting this case, we aimed to discuss the approaches to NMS and treatment modalities of NMS by the light of the literature.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Neuroleptic malignant syndrome (NMS) is neurological disorder mostly caused by an adverse reaction to neuroleptic or antipsychotic drugs. Symptoms include high fever, diaphoresis, unstable blood pressure, unconsciousness, diaphoresis muscular rigidity, and autonomic dysfunction. A 27-year-old male admitted to emergency department with altered mental status, speech disturbance, hyperthermia and diaphoresis. He had used haloperidole and clorpromazine during his hospital admission because of psychosis, and he had been prescribed oral clorpromazine 50 mg and ketiapine 100 mg daily. On the neurological examination, he had altered mental status and he was extremely rigid. The laboratory analysis revealed the creatinine phosphokinase levels as 14.428 U/L, myoglobin 2860 ng/mL, leukocyte 20.500. Liver enzymes were high and he had renal failure. He was diagnosed as neuroleptic malignant syndrome. By presenting this case, we aimed to discuss the approaches to NMS and treatment modalities of NMS by the light of the literature.

Özet

Nöroleptik malign sendrom (NMS), hayatı tehdit eden genellikle nöroleptik ve antipsikotik ilaçların yan etkilerine bağlı olarak ortaya çıkan nörolojik bir hastalıktır. Semptomlar yüksek ateş, terleme, labil hipertansiyon, bilinç bozukluğ u, kaslarda rijidite ve otonomik disfonsiyonu içerir. Yirmi yedi yaşındaki erkek hasta bilinç bozukluğu, konuşma güçlüğü, ateş ve terleme yakınması ile acil servise başvurdu. Psikoz nedeniyle hastanede yattığı dönemde haloperidol ve klorpromazin kullanım öyküsü olan hasta, halen 50 mg/gün klorpromazin ve 100 mg/gün ketiapin almaktaydı. Nörolojik muayenede bilinç bozukluğu ve kas rijiditesi vardı. Laboratuvar incelemelerinde kreatin fosfokinaz 14,428 U/L, miyoglobin 2860 ng/mL, lökosit 20,500 idi. Karaciğer enzimleri yüksekti ve böbrek fonksiyon testleri bozulmuştu. Hasta NMS olarak kabul edildi. Bu olgu sunumu ile NMS’ye yaklaşımı ve tedaviyi literatür eşliğinde tartışmayı amaçladık.

🔖

Cite This Article

KOÇ, F., KEKEÖ, Z. (2022). Neuroleptic malignant syndrome: A case report. Türkiye Acil Tıp Dergisi, Cilt: 8 - Sayı: 3, 133–135. https://ajindex.com/articles/626114

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Borovicka MC, Bond LC, Gaughan KM. Ziprasidone- and lithium-induced neuroleptic malignant syndrome. Ann Pharmacother 2006;40:139-42
  2. Adityanjee, Aderibigbe YA, Mathews T. Epidemiology of neuroleptic malignant syndrome. Clin Neuropharmacol 1999;22:151-8
  3. Addonizio G, Susman VL, Roth SD. Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry 1987;22:1004-20
  4. Gurrera RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry 1999;156:169-80
  5. Kunz M, Gomes FA, Tramontina JF, Kapczinski F. Late-onset neuroleptic malignant syndrome in a patient using olanzapine. J Clin Psychopharmacol 2007;27:303-4
  6. Norgard NB, Stark JE. Olanzapine-associated neuroleptic malignant syndrome. Pharmacotherapy 2006;26:1180-2
  7. Palakurthi HB, Parvin MM, Kaplan S. Neuroleptic malignant syndrome from aripiprazole in an agitated pediatric patient. Clin Neuropharmacol 2007;30:47-51
  8. Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004;65:464-70
  9. Fekadu A, Bisson JI. Neuroleptic malignant syndrome: diagnostic and therapeutic dilemmas. Behav Neurol 2005;16:9-13
  10. Mendhekar DN, Duggal HS. Persistent amnesia as a sequel of olanzapine-induced neuroleptic malignant syndrome. J Neuropsychiatry Clin Neurosci 2006;18:552-3
  11. Ording H, Ranklev E, Şetcher R. Investigation of malignant hyperthermia in Denmark and Sweden. Br J Anaesth 1984;56:1183-90
  12. Grebb JA. Medication-induced movement disorders. In: Sadock BJ, Sadock VA, editors. Kaplan & Sadock's Comprehensive Textbook of Psychiatry. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004. p. 1909-15
  13. Rosebush PI, Stewart T, Mazurek MF. The treatment of neuroleptic malignant syndrome. Are dantrolene and bromocriptine useful adjuncts to supportive care? Br J Psychiatry 1991;159:709-12
  14. Miyaoka H, Shishikura K, Otsubo T, Muramatsu D, Kamijima K. Diazepamresponsive neuroleptic malignant syndrome: a diagnostic subtype? Am J Psychiatry 1997;154:882.